AstraZeneca PLC (AZN) Stock Analysis
AstraZeneca PLC (AZN) is a multinational biopharmaceutical company headquartered in the UK, specializing in the discovery, development, and commercialization of prescription medicines across oncology, cardiovascular, respiratory, and immunology. Investors research AZN for its diversified drug portfolio, strong pipeline, and exposure to high-growth therapeutic areas.
Get a full AI research report on AZN
6-step deep analysis in ~90 seconds. Quick research is free — no signup.
What does AstraZeneca PLC do?
AstraZeneca generates revenue by discovering and developing prescription medicines that it manufactures and sells globally through its own commercial infrastructure and partnerships. The company operates across six primary therapeutic areas: oncology (including Tagrisso, Imfinzi, Lynparza, and Enhertu), cardiovascular and renal metabolism (Farxiga, Brilinta, Crestor), respiratory and immunology (Symbicort, Fasenra, Tezspire), vaccines and immune (Beyfortus, Synagis), and specialty care. Its business model relies on patent protection, regulatory approvals, and continuous pipeline advancement to offset patent expirations on mature products.
Bull case
- ✓Forward P/E of 14.6 suggests a lower valuation relative to the trailing P/E of 25, indicating market expectations for earnings growth as newer drugs mature and contribute to revenue.
- ✓Gross margin of 81.7% and operating margin of 23.5% demonstrate strong pricing power and operational efficiency typical of successful branded pharmaceutical companies.
- ✓PEG ratio of 1.17 indicates the stock is priced reasonably relative to expected earnings growth, suggesting the valuation may not be excessive for a company in the pharma sector.
- ✓Return on equity of 22% reflects efficient capital deployment and strong profitability relative to shareholder capital, above typical pharmaceutical industry averages.
- ✓Diversified portfolio across oncology, cardiovascular, respiratory, and vaccines reduces dependence on any single product or therapeutic area.
Bear case
- ✗Debt-to-equity ratio of 64.2% is elevated, indicating significant leverage that could constrain financial flexibility during downturns or require refinancing at higher rates.
- ✗Current ratio of 0.886 and quick ratio of 0.664 suggest potential near-term liquidity constraints, as current liabilities exceed current assets.
- ✗Trailing P/E of 25 is relatively high for the pharmaceutical sector, which may limit upside if earnings growth disappoints or market sentiment shifts.
- ✗Pharmaceutical companies face ongoing patent cliff risks as blockbuster drugs lose exclusivity; AstraZeneca's revenue depends on successful pipeline advancement to offset these expirations.
- ✗Regulatory and clinical trial risks are inherent in drug development; pipeline setbacks or safety concerns could materially impact future revenue and stock performance.
AZN valuation & financial health
AstraZeneca trades at a trailing P/E of 25 with a forward P/E of 14.6, suggesting the market is pricing in meaningful earnings growth ahead. The company's 81.7% gross margin and 23.5% operating margin reflect strong pricing and operational leverage typical of successful branded pharma. However, the 64.2% debt-to-equity ratio and current ratio below 0.9 indicate elevated financial leverage and potential near-term liquidity tightness. The 22% return on equity and 1.7% net margin demonstrate profitability, while the 1.19 PEG ratio suggests valuation is not extreme relative to growth expectations. The 1.9% dividend yield with a 47.4% payout ratio provides modest income while retaining capital for R&D and debt service.
The bottom line
AstraZeneca presents a mixed financial profile: a profitable, cash-generative pharmaceutical company with a diversified portfolio and reasonable forward valuation, offset by elevated leverage, tight liquidity ratios, and exposure to patent cliff and pipeline risks. Investors should weigh the company's strong margins and growth expectations against its debt burden and the inherent uncertainties of drug development and regulatory approval. Key factors to monitor include pipeline trial outcomes, patent expiration timelines, debt refinancing plans, and quarterly revenue trends in key therapeutic areas.
Frequently asked questions
What does AstraZeneca PLC do?
AstraZeneca is a biopharmaceutical company that discovers, develops, manufactures, and sells prescription medicines globally. It operates across oncology, cardiovascular, respiratory, immunology, vaccines, and specialty care, with a portfolio including drugs like Tagrisso, Farxiga, Symbicort, and Beyfortus.
Is AZN overvalued at a P/E of 25?
The trailing P/E of 25 is elevated relative to the forward P/E of 14.6, suggesting the market expects significant earnings growth. Whether this is justified depends on pipeline success and revenue growth; the 1.17 PEG ratio indicates valuation is not extreme relative to expected growth, but individual investors should assess pipeline risk tolerance.
What are the main risks for AZN investors?
Key risks include patent expirations on existing drugs, clinical trial failures in the pipeline, regulatory setbacks, high debt levels (64% debt-to-equity), tight liquidity (current ratio 0.886), and competitive pressure in oncology and respiratory markets.
Does AstraZeneca pay a dividend?
Yes, AstraZeneca pays a dividend with a yield of 1.9% and a payout ratio of 47.4%, meaning the company retains roughly half its earnings for reinvestment in R&D and debt reduction while returning cash to shareholders.
How profitable is AstraZeneca?
AstraZeneca is highly profitable with a gross margin of 81.7%, operating margin of 23.5%, and net margin of 17%, along with a 22% return on equity. These metrics reflect strong pricing power and operational efficiency in the pharmaceutical industry.
What is AZN's financial health?
AstraZeneca is profitable and cash-generative but carries significant debt (64% debt-to-equity) and has a current ratio below 0.9, indicating tight near-term liquidity. The company's strong margins and forward earnings growth expectations support its ability to service debt, but leverage remains a consideration.
Research AZN with AI in seconds
Company profile, financials, events, competition, risks and synthesis — automated.
Start free — no signupFor informational purposes only — not investment advice. Analysis is AI-generated from public data and may contain errors. Always do your own research.